5 (326) In stock
Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States - Transplantation and
Frontiers The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
CAR T-Cell Therapy for Cancer
Frontiers Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
Cancers, Free Full-Text
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
The CAR T Cell Story Published in healthbook TIMES Oncology Hematology
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma, Experimental Hematology & Oncology
Cureus, Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
